PerkinElmer Completes Acquisition of ViaCell

Nov 15, 2007

WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 15, 2007--PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences, today announced that it has successfully completed its acquisition of ViaCell, Inc., a biotechnology company specializing in the collection and preservation of umbilical cord blood stem cells. The acquisition expands PerkinElmer's offerings and reach in the neonatal, prenatal and maternal health markets.

ViaCell's ViaCord(R) product offering allows expectant families to preserve their baby's umbilical cord blood at the time of birth for possible future medical use in treating over 40 life-threatening diseases, including certain leukemias, immune system deficiencies, and metabolic disorders. The addition of ViaCord and ViaCell's highly qualified sales and marketing organization provides PerkinElmer with a leading offering in the rapidly growing cord blood banking business, as well as an enhanced ability to reach obstetric professionals and prospective parents. ViaCell customers will continue to benefit from ViaCord's high-quality cord blood banking offering and expertise, and now will have access to a wider range of neonatal, prenatal and maternal health solutions from PerkinElmer.

"PerkinElmer is committed to protecting the health of mothers and babies from pregnancy through birth and beyond," said Robert F. Friel, President and Chief Operating Officer, PerkinElmer. "The addition of ViaCell marks another step in our efforts to become a leading provider of innovative prenatal, neonatal and maternal healthcare solutions. We will continue to look for opportunities to build our product portfolio and provide the most comprehensive and accurate assessment of newborn and maternal health to families and their healthcare providers."

PerkinElmer is the world's leading provider of newborn screening systems, offering the world's first and only tandem mass spectrometry (MS/MS) kit cleared by the FDA as an aid to screening for inborn errors of metabolism. The Company continues to drive the advancement of newborn screening with the capability to analyze more than 40 disease markers with a single blood sample. PerkinElmer estimates that every baby screened in the U.S. today is tested using its screening tools, and has helped identify more than 100,000 infants globally who were determined to be at risk for potentially life-threatening diseases.

As part of its rapidly growing offerings for prenatal and maternal health, PerkinElmer currently offers Ultra-Screen(R), a first-trimester prenatal screening protocol designed to provide patient-specific risk assessment for certain chromosomal abnormalities, through its clinical test subsidiary, NTD Laboratories. The Company also holds a global licensing agreement to develop assay kits for the ADAM12 biochemical marker, which has broad potential in maternal health screening for fetal chromosomal abnormalities, and has secured global rights for Placental Protein 13 (PP13), a new maternal serum marker currently under investigation that has shown potential for early detection of pre-eclampsia in low-risk groups.

You must be a registered user to talk back to us.

More News from PerkinElmer Optoelectronics

Feb 06, 2009 -

PerkinElmer Expands LED Portfolio with Acquisition of Opto Technology, Inc.

Jan 30, 2009 -

PerkinElmer Announces Financial Results for the Fourth Quarter of 2008

Nov 18, 2008 -

PerkinElmer Launches Volocity 5� High Performance Imaging Acquisition and Analysis Software

Sep 16, 2008 -

PerkinElmer Launches Online Radiochemical Tool Kit To Support Customers' Critical Laboratory Requirements

Sep 16, 2008 -

PerkinElmer to Present at UBS Global Life Sciences Conference

Jul 24, 2008 -

PerkinElmer to Triple Neonatal Screening Capacity in Mexico

Jul 14, 2008 -

Dr. Alan Fletcher Joins PerkinElmer as Vice President of Bio-Discovery Business Development

Jul 08, 2008 -

PerkinElmer Appoints Its Chief Scientific Officer Daniel Marshak to Lead Greater China Operations

Jul 01, 2008 -

PerkinElmer Unveils Tailored LIMS Solutions for Water, Food and Petrochemical Laboratory Customers

Jun 16, 2008 -

PerkinElmer Receives 2008 Life Science Industry Award for Achievement in High Throughput Screening

(40) more news from PerkinElmer Optoelectronics

PerkinElmer Completes Acquisition of ViaCell news release has been viewed 698 times

SMT Machines

reflow oven profiler